📢Job alert! TOV is hiring a Patent Agent for our growing team. If you have experience in a #techtransfer office, law firm, or company and want to work with a fast-growing team & NYU's nearly $1B research enterprise, check it out! jobs.nyulangone.org/job/13931083/p…

Synthetic Protein Scientist Transforms Laboratory Discoveries into Potential Cancer Drugs | NYU Langone News nyulangone.org/news/synthetic…

Great work Mat Legut, PhD Neville Sanjana … this is going to be addressing a need in the immunotherapy space

Structure of a Bacterial ‘Drug Pump’ Reveals New Way to Counter Hospital-Borne Infection | NYU Langone News. Great work from our very own staff member’s doctoral work ⁦Douglas Brawley⁩ nyulangone.org/news/structure…

Partnership opportunity! NYU Langone Health researchers have developed new antibodies against cancer target CD99 for the treatment of #leukemia & other blood malignancies -featuring nanomolar target affinity, high target selectivity, low toxicity, & IgG framework pubmed.ncbi.nlm.nih.gov/34958778/

Partnership opportunity! NYU Langone Health's michele pagano has ID'd new small molecule inhibitors of a key enzymatic complex in #coronaviruses to combat #SARSCoV2. The compounds, when combined w/ known drugs, show therapeutic potential as pan-coronavirus antivirals pubmed.ncbi.nlm.nih.gov/34862481/

Congratulations to Michael Pacold, MD, PhD a physician-scientist at NYU Grossman School of Medicine NYU Langone Health Perlmutter Cancer Center at NYU Langone Health. Michael Pacold's lab is developing novel metabolomics tools to study the growth of tumors in nutrient and oxygen-limiting environments. #PSSCRA22 psscra.org/winners/michae…

There is a story that I have been wanting to tell for a while regarding a scientific journey that started more than 6 years ago. It’s been a really eye-opening process and I hope it can serve as an inspiration to others, especially those starting their research careers. A 🧵...

TOV is excited to be a part of the 2022 BIO Convention this week in San Diego. We look forward to connecting with industry while representing some of NYU Langone Health’s and New York University’s impactful early-stage research. #therapeutics #drugdiscovery #biotech #techtransfer #BIO2022

Some great news in the fight against malaria. The RTS,S, vaccine being used today was developed through approaches that stem from the research of NYU Langone Health's Dr. Ruth Nussenzweig and her colleagues and reports they published in 1967 and 1980. gavi.org/news/media-roo…

Great turnout for the first class in our fall course: Introduction to Biomedical Entrepreneurship - Foundations of Biomedical Startups! med.nyu.edu/research/techn…

The TOV team is at the #RESI conference in #Boston showcasing New York University's exciting portfolio of technologies and startups to #lifescience investors! If you are attending and would like to connect, please reach out.

📢Norovirus Link to Crohn’s Disease May Point to New Therapies. nyulangone.org/news/norovirus… TOV is excited to help facilitate the commercialization of this innovative, early-stage therapeutic for the treatment of #CrohnsDisease from the Cadwell Lab and Dr. Shohei Koide’s group.

A recent study led by Perlmutter Cancer Center at NYU Langone Health's Benjamin Neel has shown that a new biotechnology platform they developed might overcome ways cancer cells usually evade certain major treatments, using a two-phased approach. Learn more: bit.ly/3S7QatW

We're hiring! Join our fast-growing team as we expand our capacity to get New York University ideas into the world to maximize their impact. TOV has 2 open positions: Licensing Associate, Life Sciences Licensing Associate, Physical Sciences Learn more & apply: jobs.nyulangone.org/job-search-res…

New DNA Analysis Provides First Accurate #tuberculosis Genome The novel genome assembly tool (Bact-Builder) could spur the development of new treatments for TB and other bacterial infections Poonam Chitale Rutgers NJMS #Microbiology go.nature.com/3Xqi4Vy

Congratulations to Tezcat Biosciences, MabSwitch Inc and Lime Therapeutics on each being awarded a Bristol Myers Squibb Golden Ticket! All the best! A sincere thank you to Bristol Myers Squibb for their unwavering support of start-ups and their contributions to the advancement of the Biotech industry.

Out today in Nature Biotechnology! PhD students & postdocs: there's a trick – overlooked and underused – for having new ideas in the creative process. Talk science 1 on 1 with a science buddy that you trust and think of it as an improvisation. nature.com/articles/s4158…… Martin Lercher